Laryngeal Cryotherapy for Refractory Neurogenic Cough

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Dec 16, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called cryotherapy for patients who have a persistent cough caused by nerve issues, known as refractory neurogenic cough. The goal is to see if this treatment is safe and effective for improving cough symptoms in individuals who have not found relief from other treatments. The study is currently looking for participants aged 18 and older who have been diagnosed with this condition after ruling out other possible causes of their cough, such as allergies or asthma.

To participate, individuals must be willing to join the study, but there are some criteria that would exclude them, such as having uncontrolled reflux or other significant health issues. Participants in the trial can expect to receive the cryotherapy treatment and will be monitored to evaluate how well it works for their cough symptoms. This study is an important step in finding better solutions for those suffering from this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients 18 years or older with diagnosis of neurogenic cough
• • Neurogenic cough is a diagnosis of exclusion applied to persistent cough (8 weeks or longer)
• • Negative workup for other causes, including sinonasal allergies/chronic sinusitis, cough-variant asthma, and GERD
• • Patient willing to participate in a clinical trial
• Exclusion Criteria:
• • Uncontrolled reflux (scoring on Reflux Symptom index of 13 or higher)
• • Vocal fold abnormalities or impairment
• • History of asthma or other underlying lung condition not adequately treated or controlled
• • Uncontrolled Allergic Rhinitis (Total Nasal Symptom Score \>6, which would indicate moderate disease32)
• • Reported symptom of postnasal drip
• • Current smoker
• • Current neuromodulator medication use
• • Patient unwilling to participate in clinical trial or sign an informed consent
• • End stage medical disease with poor life expectancy
• • Medical instability deemed by the investigators as a contraindication for enrollment
• • Abnormal Chest X-ray
• • Abnormal pulmonary function testing (PFTs)
• • Positive local allergy panel (combined RAST testing)